Raymond James reiterates Outperform on Regeneron stock at $910 target

REGN looks like a classic case where the market is still underpricing platform optionality relative to the nearer-term commercial base. The key second-order effect is that a credible complement-inhibitor franchise can re-rate the whole immunology pipeline, not just the lead indication: once physicians see differentiation on durability and dosing convenience, follow-on labels become easier to penetrate and payer friction falls faster than usual. The setup is especially attractive because the market is assigning value to a single asset story while the next 12-18 months contain multiple binary readouts that can independently lift the multiple.

The bigger competitive implication is not just displacement of other C5 inhibitors, but pressure on adjacent rare-disease and ophthalmology platforms that rely on chronic administration and premium pricing. If the combination proves cleaner in both efficacy and logistics, the market may start discounting incumbents’ growth durability before the revenue numbers fully turn. That would also create a spillover benefit for TLX if investors start to view the collaboration as evidence that REGN is increasingly willing to use capital-light partnerships to broaden the pipeline without diluting margin structure.

The contrarian risk is timing: this can work fundamentally while underperforming tactically if the market de-risks the 2026 catalysts too slowly and treats the current move as already “paid for.” Another hidden risk is that early enthusiasm on the combination could overstate peak share capture if prescribers anchor to established standards in the first 6-9 months post-launch. For the next several quarters, the trade is less about absolute upside versus disappointment and more about whether each incremental data point reduces the probability-weighted gap between current valuation and the long-duration earnings stream.